Dexamethasone Administration in Oncology

Clinical Context and Guidelines

• The National Comprehensive Cancer Network recommends oral dexamethasone at 40 mg weekly in combination protocols for multiple myeloma and acute lymphoblastic leukemia 1, 2, 3
• In pediatric ALL, dexamethasone 10 mg/m²/day for 14 days during induction showed improved outcomes in patients younger than 10 years, though it carried higher osteonecrosis risk in older patients, as per the National Comprehensive Cancer Network guidelines 4
• The National Comprehensive Cancer Network suggests using IM dexamethasone when oral administration is not feasible, such as in cases of nausea, vomiting, or altered mental status, and when rapid response is required for conditions like cerebral edema or shock, with a preference for oral dexamethasone when patients can reliably take oral medications or require long-term maintenance therapy 1, 2, 5